Statins Reduce Major Vascular Events in All Age Groups
نویسندگان
چکیده
منابع مشابه
ACP Journal Club. Review: Statins reduce mortality and major vascular events in patients with no history of CV disease.
In patients with no history of cardiovascular disease (CVD), what are the benefits and harms of statins? Review scope Included studies compared statins with placebo or usual care in adults ≥ 18 years of age, and had treatment duration ≥ 12 months and follow-up ≥ 6 months. Studies in which > 10% of patients had previous CVD or in which statins were used to treat or control chronic conditions wer...
متن کاملHeart failure: statins for all?
Although there is increasing evidence of benefit in using statins to treat patients with non-ischaemic heart failure, it is not yet possible to recommend the routine use of these drugs in all heart failure patients, irrespective of the aetiology. T he endothelium is an essential structural and functional element of the cardiovascular system and constitutes the largest endocrine system in the or...
متن کاملShould all patients receive statins to reduce cancer risk after heart transplantation?
The study by Frolich et al1 in this issue of Circulation adds to the body of evidence that statins as a class of drugs have effects that reduce the chance of cancer initiation and progression, recapitulating findings showing reductions in cancer-related mortality in statin users in other major malignancies such as breast and prostate cancer.2,3 The authors are explicit in recognizing the flaws ...
متن کاملSimvastatin was cost-effective for reducing major vascular events in vascular disease or diabetes mellitus.
M e t h o d s Design: Cost-effectiveness analysis (CEA) (from the U.K. National Health Service perspective) of a randomized placebo-controlled trial (Heart Protection Study [HPS]). Allocation: {Concealed}†.* Blinding: Blinded {clinicians, patients, data collectors, and outcome assessors}†.* Follow-up period: Mean 5 years. Setting: {69 hospitals in the United Kingdom}†. Patients: 20 536 patients...
متن کاملCochrane review: dipyridamole for preventing major vascular events in patients with vascular disease.
BACKGROUND Patients enrolled in clinical trials after nondisabling cerebral ischemia have an annual risk of vascular events (death from all vascular causes, nonfatal stroke, or nonfatal myocardial infarction) of 4% to 11%. Aspirin reduces the incidence by 13%. Many trials in patients presenting with vascular disease investigated the efficacy of (addition of) dipyridamole in secondary prevention...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: AJN, American Journal of Nursing
سال: 2019
ISSN: 0002-936X
DOI: 10.1097/01.naj.0000557920.03118.d7